Vestand Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements

Vestand Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements GlobeNewswire December 02, 2025 BREA, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Vestand Incorporated (NASDAQ: VSTD) (“Vestand” or the “Company”) received a notice (the “Notice”) from Nasdaq Listing Qualifications (“Nasdaq”) on November 25, 2025 notifying the Company that as it has not yet […]

The AI Transformation Has Arrived. Now Comes the Hard Part: Securing It

(NASDAQ:CHKP), REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Artificial intelligence is transforming the enterprise at unprecedented speed. AI now underpins critical workloads, cloud operations, identity systems, code pipelines, and everyday collaboration tools. As these systems expand across hybrid cloud and edge environments, organizations face a new challenge: how to secure AI architectures that

New Book ‘Beyond the Bays’ Gives Auto Repair Shop Owners the Financial Playbook They’ve Been Missing

New Book 'Beyond the Bays' Gives Auto Repair Shop Owners the Financial Playbook They've Been Missing GlobeNewswire December 02, 2025 MOUNT AIRY, Md., Dec. 02, 2025 (GLOBE NEWSWIRE) — Many auto repair shop owners across the country face the same issues: packed bays but shrinking profit, complex financial decisions, disappearing cash flow and endless stress.

The AI Transformation Has Arrived. Now Comes the Hard Part: Securing It

The AI Transformation Has Arrived. Now Comes the Hard Part: Securing It Discover how to build resilient, prevention-first AI security — from models and agents to cloud workloads and connectivity. Live on December 4 GlobeNewswire December 02, 2025 REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Artificial intelligence is transforming the enterprise at unprecedented

Plug to Participate in the Asia-Pacific Investor Call with J.P. Morgan

(NASDAQ:PLUG), SLINGERLANDS, N.Y., Dec. 02, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, is participating this evening in the Asia-Pacific Investor conference at 8:00 PM EST. President and Chief Revenue Officer, Jose Luis Crespo, will represent Plug on the call, where he will

PrairieSky Royalty Declares Quarterly Dividend

(TSX:PSK), CALGARY, Alberta, Dec. 02, 2025 (GLOBE NEWSWIRE) — PrairieSky Royalty Ltd. (“PrairieSky“) (TSX:PSK) announced today that its Board of Directors has declared a quarterly dividend of CDN $0.26 per common share, payable in cash on January 15, 2026 to shareholders of record on December 31, 2025. This dividend is designated as an “eligible dividend”

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

(NASDAQ:BDTX), Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:IRD), RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 02, 2025 RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today

Scroll to Top